These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 23307090

  • 1. [Molecular and genetic features of gastrointestinal stromal tumors (GIST)].
    Buleje S J, Yábar B A, Guevara-Fujita M, Fujita R.
    Rev Gastroenterol Peru; 2012; 32(4):394-9. PubMed ID: 23307090
    [Abstract] [Full Text] [Related]

  • 2. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
    Künstlinger H, Binot E, Merkelbach-Bruse S, Huss S, Wardelmann E, Buettner R, Schildhaus HU.
    Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A, Boglione A.
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [Abstract] [Full Text] [Related]

  • 7. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF.
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [Abstract] [Full Text] [Related]

  • 8. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
    Martinho O, Gouveia A, Viana-Pereira M, Silva P, Pimenta A, Reis RM, Lopes JM.
    Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767
    [Abstract] [Full Text] [Related]

  • 9. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
    Miettinen M, Sobin LH, Lasota J.
    Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
    [Abstract] [Full Text] [Related]

  • 10. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E, Merkelbach-Bruse S, Büttner R, Schildhaus HU.
    Verh Dtsch Ges Pathol; 2007 Sep; 91():165-8. PubMed ID: 18314611
    [Abstract] [Full Text] [Related]

  • 11. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
    Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA.
    J Clin Oncol; 2003 Dec 01; 21(23):4342-9. PubMed ID: 14645423
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
    Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP.
    Clin Cancer Res; 2005 Jun 01; 11(11):4182-90. PubMed ID: 15930355
    [Abstract] [Full Text] [Related]

  • 18. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
    Loughrey MB, Trivett M, Beshay V, Dobrovic A, Kovalenko S, Murray W, Lade S, Turner H, McArthur GA, Zalcberg J, Waring PM.
    Histopathology; 2006 Jul 01; 49(1):52-65. PubMed ID: 16842246
    [Abstract] [Full Text] [Related]

  • 19. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
    Miselli FC, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, Fiore M, Casali PG, Bertulli R, Carbone A, Pierotti MA, Tamborini E, Pilotti S.
    Clin Cancer Res; 2007 Apr 15; 13(8):2369-77. PubMed ID: 17438095
    [Abstract] [Full Text] [Related]

  • 20. The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.
    Koh Y, Lee HE, Oh DY, Kim JH, Lee SH, Kim SH, Kim DW, Im SA, Kim TY, Heo DS, Kim WH, Bang YJ.
    Jpn J Clin Oncol; 2012 Nov 15; 42(11):1020-7. PubMed ID: 22952296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.